tbuckley/cabot-search huggingface dataset:
Adrenal Corticosteroid Therapy
Authors: Helen Morris
Journal: JAMA (1981)

<h3>To the Editor.—</h3> We are concerned that the conclusions of Klinefelter et al, in their article entitled "Single Daily Dose Prednisone Therapy" (1979;241:2721-2723), tend to minimize the degree of adrenal suppression in their patients and could lead to a false sense of security about the adrenal status of patients receiving this form of therapy. The possible need for supplemental steroids during stress is mentioned only in the abstract and not in the body of the article, where the authors state that the majority of their patients had normal adrenal function, a conclusion not substantiated by their data. The authors use the adrenocorticotropic (ACTH)-stimulation test to evaluate the function of the hypothalamic-pituitary-adrenal (HPA) axis. The test result was considered normal if there was at least a 7-μg/dL rise in plasma cortisol levels. This criterion is not adequate for a conclusion that adrenal function is normal. Barnes et al<sup>1</sup>required an
Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy
Authors: R. Klein
Journal: JAMA (1988)

The relationship between hyperglycemia, measured by glycosylated hemoglobin at the initial examination, and the four-year incidence and progression of diabetic retinopathy was examined in a population-based study in Wisconsin. Younger- (n = 891) and older-onset (n = 987) persons participating in baseline and follow-up examinations were included. Glycosylated hemoglobin was measured by microcolumn. Retinopathy was determined from stereoscopic fundus photographs. In the younger-onset group, comparing the highest with the lowest quartile of glycosylated hemoglobin, the relative risk for developing any diabetic retinopathy was 1.9; for proliferative retinopathy, 21.8; and for progression, 4.0. Among older-onset persons taking insulin, the corresponding relative risks were 1.9, 4.0, and 2.1. Among older-onset persons not taking insulin, relative risks were 4.0 for any retinopathy and 6.2 for progression. A positive relationship between incidence and progression of retinopathy and glycosylated hemoglobin remained after controlling for duration of diabetes, age, sex, and baseline retinopathy. These data suggest a strong and consistent relationship between hyperglycemia and incidence and progression of retinopathy. (<i>JAMA</i>1988;260:2864-2871)
Error in Figure Titles
Journal: JAMA Internal Medicine (2017)

Tara Gomes, MHSc; Diana Martins, MSc; Mina Tadrous, PharmD, PhD; J. Michael Paterson, MSc; Baiju R. Shah, MD, PhD; Jack V. Tu, MD, PhD; David N. Juurlink, MD, PhD; Anna Chu, MHSc; Muhammad M. Mamdani, PharmD, MA, MPH
A Physical Sign in Thyrotoxicosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hypertension
Authors: P. D RIDLEY
Journal: Cardiovascular Research (1993)

Journal Article Hypertension Get access PAUL D RIDLEY PAUL D RIDLEY Bristol, United Kingdom By John D Swales and Peter S Sever. (Pp 120; £8.95) London: Gower Medical Publishing, 1991 ISBN 0-397-44824-4 Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 27, Issue 5, May 1993, Page 891, https://doi.org/10.1093/cvr/27.5.891 Published: 01 May 1993
NEWER KNOWLEDGE OF THE THYROID
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Future Research Directions for Evaluating Human Genetic and Cancer Risk from Environmental Exposures
Authors: Richard J. Albertini, Janice A. Nicklas, J. Patrick O'Neill
Journal: Environmental Health Perspectives (1996)

The utility of biomarkers for evaluating the genotoxicity of environmental exposures is well documented.Biomarkers of both exposure and effect provide bases for assessing human- genotoxicant interactions and may be indicative of future disease risk.At present, there is little information on the predictive value of these assays for either a population or the individuals tested.This paper describes some aspects of biomarker assays, the possible use of susceptibility measures in biomonitoring protocols, and the need for evaluation of disease relevance.A population study involving epidemiologists, geneticists, toxicologists, statisticians, and physicians is proposed to determine the disease relevance of these biomarkers.
LACK OF PUBLIC TOILET FACILITIES IN CITIES.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HIV, heterosexual transmission, and women
Authors: M. E. Guinan
Journal: JAMA (1992)

THE HUMAN immunodeficiency virus (HIV) epidemic has moved into the heterosexual population in the United States. This probably started in the 1970s but was making significant inroads by 1982 as determined from a backcalculation model.<sup>1</sup>Given the methodologic difficulties in estimating HIV incidence, trend data may give the most reliable picture of the emerging epidemic. As of March 1992, a total of 12 881 patients with the acquired immunodeficiency syndrome (AIDS) had been reported who acquired their infection through heterosexual intercourse, 5100 men and 7781 women.<sup>2</sup> Women have outnumbered men in the heterosexual contact transmission category in the United States since the epidemic was recognized in 1981.<sup>3</sup>Four-year trends in reported AIDS cases show that women accounted for an increasing proportion of total cases between 1988 (10.4%) and 1991 (12.8%) and heterosexual contact accounted for a greater proportion of female cases each year from 1988 through 1991
Does Kidney Infection Cause Renal Failure?
Authors: C. Kunin
Journal: Annual Review of Medicine (1985)

CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist CD40 ...Read More
AIDS in a "state of flux" in Asia, says UN report
Authors: R. Sharma
Journal: BMJ (2001)

Drug companies neglect research into diseases affecting the poor 154, 254, 272, 217, Drugs companies are failing to develop new drugs for diseases that predominantly affect poor people because they are not profitable enough, says a report from the international medical aid agency Médecins Sans Frontières."Drugs are not developed according to public health need, but according to profitability," said Dr Bernard Pécoul, director of the agency's Campaign for Access to Essential Medicines.The report describes the research and development activities of 11 major pharmaceutical companies, representing combined sales of nearly $117bn (£78bn).The medical aid agency specifically asked them for the overall resources devoted to malaria, tuberculosis, sleeping sickness, Chagas' disease, and leishmaniasis.Eight of the 11 companies spent nothing in the last financial year on research and development on sleeping sickness, leishmaniasis, or Chagas' disease.One company did not answer the question.Two reported spending on malaria.Five reported spending on tuberculosis, but seven reported spending less than 1% of their research and development budget on any of the five diseases highlighted.Meanwhile a survey by the Pharmaceutical Research and Manufacturers of America showed that in 2000 there were eight drugs in development for impotence and erectile dysfunction, seven for obesity, and four for sleep disorders.
The impact of nonclinical factors on repeat cesarean section
Authors: R. S. Stafford
Journal: JAMA (1991)

Nonclinical factors, including the setting in which health care takes place, influence clinical decisions. This research measures the independent effects of organizational and socioeconomic factors on repeat cesarean section use in California. Of 45 425 births to women with previous cesarean sections in 1986, vaginal birth after cesarean section occurred in 10.9%. Sizable nonclinical variations were noted. By hospital ownership, rates ranged from 4.9% (for-profit hospitals) to 29.2% (University of California). Variations also existed by hospital teaching level (nonteaching hospitals, 7.0%, vs formalized teaching hospitals, 23.3%); payment source (private insurance, 8.1%, vs indigent services, 25.2%); and obstetric volume (low-volume hospitals, 5.4%, vs high-volume hospitals, 16.6%). Multiple logistic regression demonstrated that these variables had independent effects after accounting for their overlapping influences and the effects of patient characteristics. The observed variations demonstrate the prominence of nonclinical factors in decision making and question the clinical appropriateness of current practice patterns. (<i>JAMA</i>. 1991;265:59-63)
Correction to Letter.
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Authors: John M. Rossi, Sattva S. Neelapu, William Y. Go, Yueh-wei Shen, Marika Sherman, Frederick L. Locke, Nancy L Bartlett, Tanya Siddiqi, Lynn Navale, Meg Elias, Jeff Wiezorek, Adrian Bot
Journal: Blood (2015)
Influenza
Authors: A Cifu, W Levinson
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manuscripts Approved for JNCI, December 10,1962, to January 10,1963
Journal: JNCI Journal of the National Cancer Institute (1963)

Journal Article Manuscripts Approved for JNCI, December 10,1962, to January 10,1963 Get access JNCI: Journal of the National Cancer Institute, Volume 30, Issue 2, February 1963, Pages 399–400, https://doi.org/10.1093/jnci/30.2.399-b Published: 01 February 1963
HALITOSIS
Authors: BURRILL B. CROHN
Journal: JAMA (1941)

Interest in halitosis, or abnormally foul breath, has to a large extent been preempted by the oral surgeon and the rhinologist; from the references in the general literature one would surmise that it is a rare disease instead of a common condition, so little interest in the subject having been shown in the past. Every writer on the topic has emphasized the mouth, the teeth and the pharynx as sources of bad odors on the breath, attributing the fetor to decaying teeth, pyorrheal abscesses and necrotic pathologic processes in the pharynx, such as breaking-down tumors and gummas. Obviously, with the present national campaign of education and the much improved care of the teeth and the gums in children and in adults, the mouth has receded in importance as a source of bad breath; such conditions as necrotic growths are unusual and of academic interest only and play a small part.
Cardiac catheterization. Indications in patients with valvular heart disease
Authors: W. Grossman
Journal: JAMA (1975)

AS WITH any diagnostic procedure, the decision to perform cardiac catheterization must be based on a careful balance of the risk of the procedure against the anticipated value of the information. The risk of cardiac catheterization is relatively easy to assess and is low in patients with valvular heart disease, mortality being less than 0.4% in a cooperative study involving 16 catheterization laboratories.<sup>1</sup>The value of the resulting information is more difficult to define, and in general, elucidation of its meaning requires knowledge of the natural history of the patient's specific disorder. In our institution, cardiac catheterization is recommended in patients with valvular heart disease when there is a need to confirm the presence of a clinically suspected condition, define its anatomic and physiologic severity, and determine the presence or absence of associated conditions. Generally, this need arises when clinical assessment suggests that the patient is approaching, but has
Impact of the USPSTF D recommendation: Early assessment of referrals for elevated PSA and prostate biopsies in a LUGPA following statement revision.
Authors: Kathleen F. McGinley, Gordon Andrew Brown
Journal: Journal of Clinical Oncology (2013)

25 Background: In October 2011, the U.S. Preventative Services Task Force (USPSTF) posted for public comment the draft of their recommendation against prostate cancer screening. Extensive media coverage and discussion within the medical community ensued. The USPSTF released their formal statement of a D recommendation in May 2012. While the potential implications of the USPSTF recommendation upon prostate cancer screening will take years to manifest, the early impact of their recommendations upon the market is evaluable. Methods: The electronic medical record of a large urology group practice composed of 32 physicians was queried for two variables: the number of referrals for an elevated PSA and the number of individuals who underwent a prostate biopsy. A control period of October 2010-September 2011 was selected and compared to October 2011-September 2012, the twelve month period beginning with release of the USPSTF draft against prostate cancer screening. Results: From October 2010 to September 2011, 28698 patients were evaluated for an elevated PSA by 32 urologists; from October 2011 to September 2012, 25075 patients were evaluated by the same number of physicians, a difference of 12.6% following release of the USPSTF recommendations. From October 2010 to September 2011, 2465 patients underwent a prostate biopsy; from October 2011 to September 2012, 1989 had a biopsy, a difference of 19.3%. Conclusions: A marked decrease in the number of patients referred to a large urology group practice for evaluation of an elevated PSA, and an even greater decrease in the number of prostate biopsies performed, occurred in the 12 months following release of the USPSTF recommendations against prostate cancer screening.
Standards for pediatric immunization practices. Ad Hoc Working Group for the Development of Standards for Pediatric Immunization Practices
Authors: Roger H. Bernier, Vance J. Dietz, Alacia E. Lyons, Harry L. McKnight, John H. Mullen, Dennis J. O'Mara, Kay Bender, Claire V. Broome, Ann H. Cary, Vito M. Caserta, Kathleen A. Fessler, Fernando A. Guerra, Elin A. Gursky, Vince L. Hutchins, Samuel E. Katz, Janet C. Lenart, Darryl Leong, John C. Lewin, Edgar K. Marcuse, Mavis L. McGuire, Freda Mitchem, Edward A. Mortimer, Karen L. Mountain, Paul W. Nannis, Richard P. Nelson, Audrey H. Nora, Christine H. Nye, Tom Schlenker, James E. Strain, David Stevens, Phyllis E. Stubbs, F. Edgar Thompson, Ronald C. Van Buren, Vance Dietz, Kenneth J. Bart, Roger Bernier, Walter A. Orenstein
Journal: JAMA (1993)

THE RESURGENCE of measles in the United States between 1989 and 1991 was associated with 55622 reported cases,<sup>1,2</sup>11251 hospitalizations, and over 42 000 hospital days (unpublished data, Centers for Disease Control and Prevention, 1992) and 166 suspected deaths from measles.<sup>3</sup>The main cause of the epidemic was failure to vaccinate children at the recommended ages, 12 to 15 months.<sup>4</sup> For editorial comment, see p 1844. While 97% to 98% of children are vaccinated by or shortly after school entry with four doses of diphtheria and tetanus toxoids and pertussis vaccine, three doses of oral poliovirus vaccine, and one dose of measles, mumps, rubella vaccine, series-complete immunization levels among preschool children are considerably lower. Recent surveys of school entrants in nine cities that measured immunization status as of the second birthday documented that only 52% to 71% had been vaccinated against measles.<sup>5</sup>Series-complete immunization levels ranged
Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data
Authors: Harry Janssen, Jinlin Hou, Tarik Asselah, Henry Chan, Fabien Zoulim, Yasuhito Tanaka, Ewa Janczewska, Ronald Nahass, Stefan Bourgeois, Maria Buti, Pietro Lampertico, Oliver Lenz, Thierry Verbinnen, Joris J. Vandenbossche, Willem Talloen, Michael Biermer, Ronald Kalmeijer, Maria Beumont-Mauviel, Umesh Shukla
Journal: Journal of Hepatology (2020)
Cost savings and prescribing protocols for nonsteroidal anti-inflammatory drugs
Authors: B. M. Rothschild
Journal: JAMA (1996)

<h3>To the Editor.</h3> —The article by Dr Jones and colleagues<sup>1</sup>presents an important but limited perspective of nonsteroidal anti-inflammatory drug (NSAID) prescription. While NSAID expenses are substantial, the major expenses are actually indirect—treatment of adverse effects and inadequate treatment of underlying diseases. Clinicians may wonder if cost savings still exist once the costs of treating ulcers, gastrointestinal bleeding, and other complications are considered. Given that 30% of indomethacin recipients have adverse effects of sufficient severity to require discontinuation,<sup>2</sup>it is surprising that indomethacin would be considered a first-line medication. Physician perception of patient harm may not accurately reflect patient experience. Chart review (to document adverse effects, hospitalizations, or both) would be of interest. Patients who develop hospitalization-requiring adverse effects of medication often find themselves under the care of another physician (for that hospitalization) and may elect to obtain subsequent care elsewhere. Thus, physician perception may underestimate the frequency